VTAK Acquires 20% Interest in Creatd's Subsidiary Fly Flyte, Inc.
MWN-AI** Summary
Creatd, Inc. (OTCQB: CRTD) has announced a strategic partnership with Catheter Precision, Inc. (NYSE American: VTAK) through the acquisition of a 20% equity stake in its subsidiary, Fly Flyte, Inc. This stake was acquired via a secondary purchase from an existing shareholder. This collaboration aligns with Creatd's strategy to foster technology-driven subsidiaries that exhibit scalable infrastructure and long-term growth potential, while ensuring Fly Flyte maintains its operational independence.
Jeremy Frommer, CEO of Creatd, highlighted the company’s commitment to building a small-cap portfolio that capitalizes on the contraction in middle markets over the past two decades. He emphasized the company's strategy of integrating services across banking, investment, advisory, and operational efficiency to support growth-oriented companies, paving the way for potential transitions to publicly listed entities.
Fly Flyte represents an innovative approach to regional aviation services, emphasizing accessibility, convenience, and technology. Leveraging AI-enabled operations, the company utilizes certified aircraft and established routes to enhance operational effectiveness, positioning itself for both immediate revenues and long-term expansion.
Creatd’s investment in Fly Flyte is part of a broader strategy to bolster its portfolio of technology-driven companies in sectors such as aviation, media, and advisory services. By implementing a shared services model, Creatd aims to elevate efficiency, improve profit margins, and expand the market reach of its portfolio companies.
This acquisition further emphasizes Creatd's dedication to fostering growth within its subsidiaries and leveraging additional industry expertise through VTAK’s involvement in Fly Flyte, which is already operational and positioned for significant development in the rapidly evolving aviation landscape.
MWN-AI** Analysis
Creatd, Inc. (OTCQB: CRTD) has recently made strategic strides with the acquisition of a 20% equity interest in its subsidiary Fly Flyte, Inc. by Catheter Precision, Inc. (NYSE American: VTAK). This partnership not only expands Fly Flyte’s investor base but also aligns with Creatd’s broader strategy of enhancing its portfolio of technology-driven companies. As an analyst, it is essential to evaluate the implications of this acquisition on stakeholders and potential investors.
The collaboration with VTAK signifies confidence in Fly Flyte's innovative approach to regional aviation, which emphasizes accessibility and technological advancements. This sets the stage for increased scalability and revenue growth in a market ripe with opportunity. Given VTAK's NYSE listing, this partnership brings added credibility and the potential for substantial financial backing, positioning Fly Flyte favorably within a burgeoning industry.
Creatd's commitment to fostering interlinked services among its subsidiaries indicates a unified approach that could yield cost efficiencies and improved margins. This structure supports companies as they progress from small-cap status toward potential uplisting, fostering investor confidence.
From a market perspective, investors considering positions in Creatd or Fly Flyte should note the significance of the aviation sector’s ongoing evolution, accelerated post-pandemic. Unique, technology-driven services like those offered by Fly Flyte, especially when combined with a strong capital partner, provide a definitive competitive edge.
However, prospective investors should also remain cognizant of market challenges, including regulatory nuances and operational risks inherent in aviation. With forward-looking statements to exercise caution, stakeholders must weigh the promise shown by partnership developments with the inherent uncertainties of growth trajectories. Overall, Creatd's strategy reflects optimism and provides a compelling narrative for investment in a dynamic sector.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
- Strategic Partnership: Creatd expanded Fly Flyte’s investor network by adding NYSE-listed VTAK as an investor in its subsidiary.
- Portfolio Expansion: Creatd continues advancing its portfolio strategy through multiple active acquisition discussions.
- Innovation in Aviation: Fly Flyte, Inc. is transforming regional aviation through accessibility, convenience, and technology-driven operations.
NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Creatd, Inc. (OTCQB: CRTD) announced that Catheter Precision, Inc. (NYSE American: VTAK) has acquired a 20% equity interest in Fly Flyte, Inc., its subsidiary, through a secondary purchase from an existing shareholder. The transaction aligns with Creatd’s strategy of nurturing technology-enabled subsidiaries with scalable infrastructure and long-term value creation potential while maintaining Fly Flyte’s operational independence and strategic focus. Creatd welcomes VTAK as a partner in Flyte’s continued growth and success.
“Creatd is committed to building a portfolio of operating companies in the small-cap space,” said Jeremy Frommer, CEO of Creatd, Inc. “We see an opportunity to address the white space created by the contraction of middle markets over the last two decades. By integrating capabilities from banking, investing, advisory, branding, investor relations, financial analysis, and operational leverage, we can build a foundation of interlinked services to support growth-driven companies and provide pathways for them to scale or transition to listed entities.”
Fly Flyte is operational today, providing AI-enabled regional aviation services designed to increase accessibility and convenience. The company leverages certified aircraft, established routes, and scalable infrastructure to deliver real-time revenue while positioning for long-term expansion.
About Creatd:
Creatd, Inc. (OTCQB: CRTD) acquires and grows technology-driven companies in aviation, media, and advisory services. Through its shared services model, Creatd enables its portfolio companies to scale efficiently, improve margins, and expand market reach. For more information, visit www.creatd.com.
Contact:
ir@creatd.com
Forward-Looking Statements:
This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements include all statements, other than statements of historical fact, regarding our current views and assumptions with respect to future events regarding our business and our expectations with respect to the completion of the offering, the satisfaction of customary closing conditions related to the offering and the additional closings, the anticipated use of proceeds therefrom, and other statements that are predictive in nature. These statements can be identified often, but not always, through the use of words or phrases such as “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimated,” “intends,” “plans,” “believes” and “projects,” and may involve estimates and uncertainties which could cause actual results to differ materially from those expressed in the forward-looking statements. We caution that the factors described herein could cause actual results to differ materially from those expressed in any forward-looking statements we make and that investors should not place undue reliance on any such forward-looking statements. Further, any forward-looking statement speaks only as of the date on which such statement is made, and we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of anticipated or unanticipated events or circumstances. New factors emerge from time to time, and it is not possible for us to predict all of such factors. Such factors and risks include, among others, market and other risks, that the additional closings after today may not occur if certain closing conditions are not met, and that there can be no assurance that the Company will successfully uplist to a national securities exchange. Further, we cannot assess the impact of each such factor on our results of operations or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. This press release contains forward-looking statements and is qualified in its entirety by, and should be read together with, the cautionary statements, risk factors and other disclosures contained in the Company’s filings with the SEC and OTC Markets.
FAQ**
How does the investment from "Catheter Precision, Inc. VTAK" align with Creatd's long-term vision for Fly Flyte, particularly in the context of enhancing regional aviation technology and operations?
What specific benefits does "Catheter Precision, Inc. VTAK" bring to Fly Flyte beyond financial support, and how might these enhance operational independence and strategic focus?
In light of the equity stake acquired by "Catheter Precision, Inc. VTAK," how does Creatd plan to leverage this partnership to expand Fly Flyte’s market reach and scalability within the regional aviation sector?
As Creatd engages in multiple acquisition discussions, how does the partnership with "Catheter Precision, Inc. VTAK" influence its portfolio strategy and the potential for future collaborations in the aviation industry?
**MWN-AI FAQ is based on asking OpenAI questions about Catheter Precision Inc. (NYSE: VTAK).
NASDAQ: VTAK
VTAK Trading
35.81% G/L:
$1.8878 Last:
54,556,101 Volume:
$2.02 Open:
